1. Home
  2. STTK vs BCAL Comparison

STTK vs BCAL Comparison

Compare STTK & BCAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.10

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Logo Southern California Bancorp

BCAL

Southern California Bancorp

HOLD

Current Price

$19.03

Market Cap

578.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
BCAL
Founded
2016
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
538.3M
578.3M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
STTK
BCAL
Price
$6.10
$19.03
Analyst Decision
Buy
Buy
Analyst Count
7
3
Target Price
$10.00
$20.67
AVG Volume (30 Days)
522.7K
138.5K
Earning Date
05-01-2026
04-28-2026
Dividend Yield
N/A
2.15%
EPS Growth
53.02
777.27
EPS
N/A
0.42
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6.67
P/E Ratio
N/A
$45.26
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$14.07
52 Week High
$8.33
$20.47

Technical Indicators

Market Signals
Indicator
STTK
BCAL
Relative Strength Index (RSI) 42.55 57.20
Support Level $5.85 $18.62
Resistance Level $6.81 $19.18
Average True Range (ATR) 0.52 0.36
MACD -0.12 -0.01
Stochastic Oscillator 23.03 72.87

Price Performance

Historical Comparison
STTK
BCAL

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About BCAL Southern California Bancorp

California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.

Share on Social Networks: